JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Published Online First: 12 May 2006. doi:10.1136/jcp.2005.035717
Journal of Clinical Pathology 2007;60:307-310
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2005.035717v1
60/3/307    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stadlmann, S.
Right arrow Articles by Singer, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stadlmann, S.
Right arrow Articles by Singer, G.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Ovarian Cancer

ORIGINAL ARTICLE

Expression of peroxisome proliferator activated receptor {gamma} and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma

Sylvia Stadlmann1, Uwe Gueth2, Edward Wight2,*, Leoni A Kunz-Schughart3, Arndt Hartmann3, Gad Singer1,*

1 Institute of Pathology, University Hospital Basel, Basel, Switzerland
2 Department of Gynecology and Obstetrics, University Hospital Basel, Basel, Switzerland
3 Institute of Pathology, University of Regensburg, Regensburg, Germany

Correspondence to:
PD Dr G Singer
Institute of Pathology, University Hospital Basel, Schönbeinstrasse 40, CH-4031 Basel, Switzerland; gsinger{at}uhbs.ch Aim: Peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) has emerged as a potential therapeutic target in several types of cancer. In ovarian carcinomas, limited and conflicting data on PPAR{gamma} protein expression have been reported.

Methods: The immunoexpression of PPAR{gamma} and its putative target cyclo-oxygenase 2 (COX2) was investigated in tumour tissues from 80 patients with primary and corresponding recurrent ovarian serous carcinomas after conventional platinum-based chemotherapy.

Results: PPAR{gamma} expression was observed in 29% of primary and recurrent carcinomas. In the recurrent tumours, PPAR{gamma} expression inversely correlated with COX2 overexpression in both chemosensitive (p = 0.02) and chemoresistant (p = 0.04) carcinomas.

Conclusions: The data indicate that PPAR{gamma} may represent a potential target for second-line treatment in ovarian cancers.

Abbreviations: COX2, cyclo-oxygenase 2; IHC, immunohistochemistry; PPAR{gamma}, peroxisome proliferator-activated receptor {gamma}; TMA, tissue microarray






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.